drugset / Trial / NCT05338723
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
RandomizedParallel-groupOpen-labelPrevention
Summary
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.
Timeline
- Start
- 2020-09-15
- Primary completion
- 2023-09-15
- Completion
- 2023-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rosuvastatin | Small molecule | 20 mg | Oral |